Peroxisome proliferators currently include a broad spectrum of synthetic and naturally occurring compounds, such as certain hypolipidemic drugs (e.g. clofibrate), leukotriene antagonists, phthalate ester plasticizers, herbicides, solvents, and the naturally occurring steroid, dehydroepiandrosterone. Despite their structural diversity, peroxisome proliferators induce qualitatively predictable immediate and delayed pleiotropic responses in rats and mice: the immediate responses consist of hepatomegaly, proliferation of peroxisomes in hepatocytes, and the induction of several hepatic enzymes, particularly those responsible for lipid metabolism, and the delayed responses include the development of hepatocellular carcinomas. Peroxisome proliferators, irrespective of their structural diversity, are found to be nonmutagenic (nongenotoxic) in that they do not directly damage DNA, thereby leading to out hypothesis that the development of liver tumors is attributable to sustained induction of peroxisome proliferation and ensuing metabolic perturbations resulting from a receptor-mediated mechanism. These agents activate peroxisome proliferator-activated receptor alpha (PPARalpha), a nuclear receptor, and sustained induction of PPARalpha-mediated peroxisome proliferation and other metabolic alterations are considered the basis for the development of liver tumors. This raises some intriguing questions about cell/tissue specificity and possible differences in species sensitivity of this response and its presumed implications. A major focus of our ongoing research is to generate fundamental information, which can provide insights into the molecular complexity of the unique pleiotropic responses, so that meaningful extrapolations can be made regarding species sensitivity and cell specificity of gene activation. We propose the following specific aims: 1) investigate the functional implications of the disruption of genes of peroxisomal beta-oxidation system and the relationship of beta-oxidation to PPARalpha-ligand metabolism; 2) generate """"""""humanized"""""""" mouse models of PPARalpha expression to evaluate peroxisome proliferator response in an attempt to understand the basis for species differences in response; 3) explore the role of H2O2- generating peroxisomal oxidases in carcinogenesis using the in vitro/in vivo molecular approaches and delineate the mechanism by which H2O2 initiates the cascade of events leading to neoplastic transformation; and 4) generate molecular portraits of liver with peroxisome proliferation induced by synthetic peroxisome proliferators, or occurring spontaneously in fatty acyl-CoA oxidase null mice to identify and characterize novel genes during the process of carcinogenesis.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM023750-29
Application #
6753620
Study Section
Special Emphasis Panel (ZRG1-ET-2 (03))
Program Officer
Okita, Richard T
Project Start
1997-07-01
Project End
2005-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
29
Fiscal Year
2004
Total Cost
$439,351
Indirect Cost
Name
Northwestern University at Chicago
Department
Pathology
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Huang, Jiansheng; Jia, Yuzhi; Fu, Tao et al. (2012) Sustained activation of PPAR? by endogenous ligands increases hepatic fatty acid oxidation and prevents obesity in ob/ob mice. FASEB J 26:628-38
Vluggens, Aurore; Reddy, Janardan K (2012) Nuclear receptors and transcription factors in the development of fatty liver disease. Curr Drug Metab 13:1422-35
Bai, Liang; Jia, Yuzhi; Viswakarma, Navin et al. (2011) Transcription coactivator mediator subunit MED1 is required for the development of fatty liver in the mouse. Hepatology 53:1164-74
Huang, Jiansheng; Viswakarma, Navin; Yu, Songtao et al. (2011) Progressive endoplasmic reticulum stress contributes to hepatocarcinogenesis in fatty acyl-CoA oxidase 1-deficient mice. Am J Pathol 179:703-13
Matsumoto, Kojiro; Huang, Jiansheng; Viswakarma, Navin et al. (2010) Transcription coactivator PBP/MED1-deficient hepatocytes are not susceptible to diethylnitrosamine-induced hepatocarcinogenesis in the mouse. Carcinogenesis 31:318-25
Stumpf, Melanie; Yue, Xiaojing; Schmitz, Sandra et al. (2010) Specific erythroid-lineage defect in mice conditionally deficient for Mediator subunit Med1. Proc Natl Acad Sci U S A 107:21541-6
Vluggens, Aurore; Andreoletti, Pierre; Viswakarma, Navin et al. (2010) Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform [corrected]. Lab Invest 90:696-708
Hall, Angela M; Brunt, Elizabeth M; Chen, Zhouji et al. (2010) Dynamic and differential regulation of proteins that coat lipid droplets in fatty liver dystrophic mice. J Lipid Res 51:554-63
Jia, Yuzhi; Viswakarma, Navin; Fu, Tao et al. (2009) Conditional ablation of mediator subunit MED1 (MED1/PPARBP) gene in mouse liver attenuates glucocorticoid receptor agonist dexamethasone-induced hepatic steatosis. Gene Expr 14:291-306
Li, Hui; Gade, Padmaja; Nallar, Shreeram C et al. (2008) The Med1 subunit of transcriptional mediator plays a central role in regulating CCAAT/enhancer-binding protein-beta-driven transcription in response to interferon-gamma. J Biol Chem 283:13077-86

Showing the most recent 10 out of 104 publications